Midatech Pharma PLC (MTP): Price and Financial Metrics
MTP Stock Summary
- With a market capitalization of $9,620,642, Midatech Pharma Plc has a greater market value than just 2.55% of US stocks.
- Revenue growth over the past 12 months for Midatech Pharma Plc comes in at -56.17%, a number that bests merely 5.1% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for MTP comes in at -182.08% -- higher than that of merely 1.46% of stocks in our set.
- Stocks that are quantitatively similar to MTP, based on their financial statements, market capitalization, and price volatility, are GNFT, VNE, DBVT, ONTX, and IMOS.
- MTP's SEC filings can be seen here. And to visit Midatech Pharma Plc's official web site, go to www.midatechpharma.com.
MTP Stock Price Chart Interactive Chart >
MTP Price/Volume Stats
|Current price||$2.03||52-week high||$7.07|
|Prev. close||$2.05||52-week low||$1.23|
|Day high||$2.10||Avg. volume||839,402|
|50-day MA||$2.42||Dividend yield||N/A|
|200-day MA||$2.08||Market Cap||25.73M|
Midatech Pharma PLC (MTP) Company Bio
Midatech Pharma PLC focuses on the development and commercialization of multiple, high-value, targeted therapies for major diseases with high unmet medical need in the nanomedicine field.
MTP Latest News Stream
|Loading, please wait...|
MTP Latest Social Stream
View Full MTP Social Stream
Latest MTP News From Around the Web
Below are the latest news stories about Midatech Pharma Plc that investors may wish to consider to help them evaluate MTP as an investment opportunity.
The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 24) F-star Therapeutics, Inc. (NASDAQ: FSTX) IDEAYA Biosciences, Inc. (NASDAQ: IDYA) Orphazyme A/S (NASDAQ: ORPH) Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 24) Adagene Inc. (NASDAQ: ADAG) Biophytis SA (NASDAQ: BPTS) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Connect Biopharma Holdings Limited (NASDAQ: CNTB) (went public Friday) Decibel Therapeutics, Inc. (NASDAQ: DBTX) Dyne Therapeutics, Inc. (NASDAQ: DYN) Epizyme, Inc. (NASDAQ: EPZM) Evaxion Biotech A/S (NASDAQ: EVAX) Finch Therapeutics Group, Inc. (NASDAQ: FNCH) (went public Friday) Forma Therapeutics Holdings, Inc. (N...
Non-binding Heads of Terms for Co-development of MTX110; Unaudited Headline Results for the Year Ended 31 December 2020ABINGDON, UK / ACCESSWIRE / March 25, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the Company has agreed non-binding Heads of Terms for the co-development of MTX110 and its unaudited headline results for the year ended 31 December 2020.
ABINGDON, OXFORDSHIRE / ACCESSWIRE / February 17, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has issued to certain US investors 61,363 American Depositary Shares (“ADSs”), representing 306,815 ordinary shares of 0.1p each in the Company (“New Ordinary Shares”), in connection with the… Read More »Midatech Pharma PLC Announces Exercise of Warrants and Issue of Equity
ABINGDON, OXFORDSHIRE / ACCESSWIRE / February 17, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has issued to .
Midatech Pharma PLC 15 February 2021 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent…
MTP Price Returns
Continue Researching MTPWant to do more research on Midatech Pharma Plc's stock and its price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!